Microglia Activation Assay Service

Creative Biolabs provides custom microglia activation assay services for researchers who need to determine whether a disease-relevant stimulus, therapeutic candidate, biomaterial, genetic perturbation, or biological sample changes microglial state and function.

Custom Microglia Activation Assays Built Around Your Study Question

We support studies ranging from rapid compound ranking to mechanistic neuroinflammation programs by combining fit-for-purpose microglia models with defined activation paradigms and orthogonal readouts. Depending on the research question, support can include model selection, stimulation and dose-range design, assay development, positive and negative control qualification, imaging, cytokine and chemokine measurement, gene and protein analysis, inflammasome testing, phagocytosis or neurotoxicity endpoints, data normalization, statistical analysis, and an interpretation-ready report. Related capabilities can be integrated through our microglia-related assay services and broader neuroinflammation assay services.

Our team can support research needs such as:

• Screening compounds or biologics for suppression or enhancement of microglial reactivity.
• Comparing inflammatory stimuli, priming sequences, concentrations, and exposure times.
• Profiling patient-derived, iPSC-derived, primary, or immortalized microglia under matched conditions.
• Measuring target engagement together with downstream cytokine, signaling, morphology, viability, or phagocytosis responses.
• Evaluating neuroinflammatory mechanisms in microglia alone or in neuron-glia co-culture and organoid contexts.
• Developing a reproducible assay package suitable for lead optimization, mechanism-of-action work, or transfer into a larger screening program.

What the Service Can Be Configured to Answer

Before selecting markers, we define the comparison that the data must resolve. For an inhibitor program, this may be the concentration-response relationship against a robust activation control. For disease modeling, it may be whether a disease-associated genotype or protein aggregate shifts basal state, lowers the activation threshold, delays resolution, or alters the balance between inflammatory output and debris clearance. For a safety study, it may be whether a test article provokes cytokine release or cellular stress in the absence of the intended stimulus.

Typical project questions include:

• Does the test article reduce a stimulus-induced signal without reducing cell number or metabolic viability?
• Is the response observed across biological replicates, donors, or cell sources?
• Does the candidate affect early pathway activation, late secreted mediators, or both?
• Is altered morphology accompanied by molecular or functional changes?
• Does a treatment normalize a disease-associated microglial response while preserving phagocytic competence?

Microglia Models Available for Activation Studies

Model choice determines biological relevance, throughput, baseline state, and the amount of optimization required. Creative Biolabs can help select one model or create a staged plan in which a robust screening model is followed by confirmation in a more translational system.

Immortalized Microglia for Assay Development and Screening

BV2 or other established microglial cell lines can provide a practical starting point for concentration-range finding, stimulus optimization, pathway interrogation, and moderate-throughput screening. Their reproducibility is useful when the primary objective is to compare many test conditions. The project plan can include a confirmatory tier in primary or iPSC-derived microglia to address the limitations of transformed cell models.

Primary and iPSC-Derived Microglia for Translational Studies

Primary cultures preserve important features of native microglia but require attention to isolation-associated activation, culture duration, species, age, and donor variability. Creative Biolabs can coordinate activation studies with its primary microglia culture and isolation service. For human genetics, donor comparison, and disease modeling, our iPSC-derived microglia generation service can provide a renewable model that supports matched control, patient, or isogenic study designs. Identity and baseline-state checks may include microglial markers such as IBA1, TMEM119, P2RY12, CX3CR1, TREM2, and PU.1, selected according to the model and study objective.

Microglia in Multicellular Neural Systems

Microglial activation can be evaluated in systems where neuronal or astrocytic signals influence the response. The neuron, astrocyte and microglia co-culture assay service can connect microglial state with neuronal viability, neurite integrity, synaptic markers, or astrocyte reactivity. For a three-dimensional context, the microglia-containing brain organoid modeling service can support studies of migration, spatial localization, cell-cell interactions, and sustained neuroinflammatory phenotypes.

Activation and Modulation Paradigms

Stimulus selection is based on the mechanism being modeled, not on a generic activated-versus-resting label. We can assess acute induction, priming, sequential challenge, chronic exposure, washout and recovery, or candidate pretreatment and rescue. Concentration and time-course pilot studies are used when the response window is unknown or when a strong stimulus risks masking partial pharmacology.

• Innate immune receptor activation: LPS/TLR4, selected TLR agonists, or other pattern-recognition receptor ligands; useful for inflammatory pathway and candidate-inhibition studies.
• Cytokine-driven activation: IFN-gamma, TNF-alpha, IL-1beta, or defined combinations; useful for stimulus-specific response profiling and priming studies.
• Inflammasome activation: A priming signal followed by ATP or another second signal; useful for NLRP3, caspase-1, IL-1beta, IL-18, and pyroptosis-related endpoints.
• Neurodegeneration-associated challenge: Amyloid-beta species, alpha-synuclein preparations, myelin debris, apoptotic material, or other disease-relevant substrates, with material qualification built into the plan.
• Damage and stress signals: ATP, HMGB1-related signaling, oxidative stress, excitotoxic conditioned media, or injury-associated factors selected for the disease context.
• Immunoregulatory modulation: IL-4, IL-13, TGF-beta, CSF1/IL-34 context, pathway inhibitors, neutralizing antibodies, genetic perturbations, or candidate therapeutics.

For projects centered on endotoxin-driven inflammation, the activation assay can be paired with the LPS-induced neuroinflammation assay service. Sequential IFN-gamma/LPS or LPS/ATP designs can also be used when priming order is mechanistically important. Vehicle controls, stimulus-only controls, reference inhibitors, and test-article-only controls are included as appropriate so that pathway suppression can be separated from assay interference or toxicity.

Multi-Parameter Readouts for Microglia Activation

A strong assay links at least two evidence layers. The exact panel is chosen to fit the expected biology, sample volume, throughput, and decision threshold. Readouts can be collected at matched or staggered time points to distinguish early signaling from later transcriptional, secretory, morphological, and functional consequences.

Imaging and Morphology

High-content or targeted imaging can measure cell area, soma size, circularity, process number or length, branching, ramification, nuclear features, and marker intensity. Immunocytochemistry may include IBA1, CD68, TMEM119, P2RY12, TREM2, lysosomal markers, or pathway-specific proteins. Automated segmentation, plate-position controls, and per-cell distributions can reveal heterogeneous responses that are hidden by well-level averages.

Cytokines, Chemokines, and Soluble Mediators

Supernatant analysis can quantify TNF-alpha, IL-1beta, IL-6, IL-18, CXCL10, CCL2, and other project-specific mediators using singleplex or multiplex methods. Nitrite, prostaglandin-related markers, or soluble damage signals can be added when relevant. Our cytokine release assay service can be integrated when the primary endpoint is secreted inflammatory output or when a broader mediator panel is required.

Gene Expression and Signaling

RT-qPCR, immunoblotting, immunofluorescence, flow cytometry, or targeted protein assays can assess NF-kappaB and MAPK pathway activity, STAT signaling, NLRP3, caspase-1, iNOS, COX-2, TREM2-related pathways, or a custom marker panel. Early phospho-signaling time points can be paired with later mRNA and protein endpoints to establish temporal coherence and improve mechanism-of-action interpretation.

Inflammasome and Cell-Health Endpoints

Inflammasome-focused designs may include NLRP3 expression, cleaved caspase-1, caspase-1 activity, mature IL-1beta and IL-18 release, LDH release, membrane integrity, or live/dead imaging. Cell number, nuclear count, metabolic viability, apoptosis, and nonspecific cytotoxicity are measured as needed to prevent a toxic concentration from being misclassified as an anti-inflammatory effect.

Functional Consequences

Activation-state data can be connected with fluorescent particle, myelin, amyloid, synaptosome, apoptotic-cell, or other substrate uptake through the microglia phagocytosis assay service. In co-culture, conditioned-media, or transwell studies, microglial responses can be related to neuronal survival, neurite morphology, synaptic proteins, oxidative stress, or astrocyte activation. An astrocyte-related assay service may be incorporated when glial cross-talk is central to the study.

How We Select a Readout Panel

For a screening project, the primary endpoint should be robust, scalable, and close to the intended mechanism, while a smaller orthogonal panel protects against false positives. For a mechanistic project, temporal coverage and pathway placement are more important than raw throughput. For donor or genotype comparisons, baseline normalization, biological replication, and batch balancing are emphasized. Example configurations include:

• Rapid candidate ranking: one primary cytokine or imaging endpoint, nuclear count/viability, reference inhibitor, and concentration response.
• Mechanism confirmation: early phospho-signaling, pathway protein or transcript, late secreted mediator, and a functional endpoint.
• Inflammasome study: priming readout, NLRP3/caspase-1 activation, mature cytokine release, and membrane-integrity control.
• Disease-model comparison: identity/baseline panel, stimulus-response curve, multiple donors or isogenic lines, and one disease-relevant function.

Research Applications

Microglia activation assays can be adapted to multiple stages of neurological research and therapeutic development. Common applications include:

• Neuroinflammation drug discovery: Screen and rank small molecules, antibodies, peptides, oligonucleotides, gene-modifying approaches, or other candidates using concentration-response and orthogonal confirmation.
• Alzheimer's and proteinopathy research: Evaluate responses to amyloid-beta, tau-associated material, alpha-synuclein, or disease-relevant conditioned media, with phagocytosis and neuronal-impact endpoints when needed.
• Multiple sclerosis and demyelination studies: Test responses to myelin debris, inflammatory cytokines, inflammasome signals, or candidate regulators of clearance and tissue-damage pathways.
• Genetic and target-validation programs: Compare knockdown, knockout, overexpression, risk variants, patient-derived lines, and isogenic controls across basal and challenged conditions.
• Biologics and advanced-therapy safety: Assess unintended microglial cytokine release, stress, or activation caused by biologics, delivery systems, nanoparticles, or cell-therapy-related materials.
• Mechanism-of-action studies: Place candidate activity at receptor, signaling, transcriptional, inflammasome, secretory, morphological, or functional levels.
• Human translation: Confirm findings from screening models in primary or iPSC-derived human microglia and multicellular neural systems.

Related Research

The following open-access studies illustrate why microglia activation is best evaluated with quantitative, multi-parameter readouts.

Quantitative Morphology and Activation-Marker Analysis

Kozlowski and Weimer developed an automated approach for measuring microglial morphology and applied it to LPS-induced activation in vivo. Their results connect morphometric features such as soma size, roundness, and cell perimeter with IBA-1 and CD68 measurements. The study supports an assay-design principle used in this service: morphology becomes more informative when it is quantified per cell and interpreted alongside molecular activation markers rather than used as a stand-alone visual observation.

Fig. 1 Morphometric parameters that quantitatively capture LPS-induced microglia morphology change and activation-marker expression.^1,3

Orthogonal Confirmation of NLRP3 Inflammasome Activation

Deng and colleagues used LPS/ATP-challenged BV2 microglia to confirm NLRP3 inflammasome activation across several evidence layers. The figure combines NLRP3 transcription and protein, cleaved caspase-1, caspase-1 activity, and IL-1beta/IL-18 secretion, with the NLRP3 inhibitor MCC950 as a mechanistic control. This type of orthogonal design helps distinguish pathway activation from a single noisy endpoint and is directly relevant to inhibitor characterization and inflammasome-focused microglia studies.

Fig. 2 LPS/ATP activates the NLRP3 inflammasome in BV2 microglia, with MCC950 used as an inhibitory control.^2,3

Frequently Asked Questions

1. Which microglia models can be used for activation assays?

   Creative Biolabs can configure activation studies with immortalized microglial cell lines, primary rodent or human microglia, iPSC-derived microglia, and microglia in neuron-glia co-cultures or organoid systems. Model selection is based on the required throughput, species, donor or genotype question, biological context, and need for translational confirmation.

2. How do you determine whether microglia are activated?

   We do not rely on one marker alone. A fit-for-purpose panel may combine quantitative morphology, activation or homeostatic markers, cytokine and chemokine release, gene or protein expression, signaling, inflammasome activity, viability, phagocytosis, or neural-cell impact. The combination is selected according to the stimulus and decision the study must support.

3. Which stimuli can be evaluated in a microglia activation assay?

   Options can include LPS or other innate immune receptor agonists, IFN-gamma, TNF-alpha, IL-1beta, ATP-based inflammasome activation, amyloid-beta, alpha-synuclein, myelin debris, apoptotic material, oxidative or injury-related signals, conditioned media, and customer-provided stimuli. Concentration, sequence, and exposure time are optimized when necessary.

4. Can the service assess anti-inflammatory potency and mechanism of action?

   Yes. Candidate compounds or biologics can be tested in concentration-response designs with stimulus-only, vehicle, reference-inhibitor, test-article-only, and cell-health controls. Early signaling, downstream mediator release, morphology, inflammasome activity, and functional endpoints can be combined to determine where the candidate acts and whether the effect is separated from cytotoxicity.

5. Can microglia activation be linked to phagocytosis or neurotoxicity?

   Yes. Activation-state measurements can be paired with uptake of fluorescent particles, myelin, amyloid, synaptosomes, apoptotic cells, or other substrates. In co-culture or conditioned-media studies, microglial responses can also be connected with neuronal viability, neurite integrity, synaptic markers, oxidative stress, or astrocyte reactivity.

6. What information is needed to design a custom study?

   Helpful starting information includes the biological question, preferred cell model or species, test article and vehicle, proposed stimulus, expected mechanism, available sample amount, target readouts, desired throughput, and comparison groups. If these parameters are not yet defined, Creative Biolabs can recommend a pilot study to establish the response window and final assay design.

References

1. Kozlowski, Cleopatra, and Robby M. Weimer. "An Automated Method to Quantify Microglia Morphology and Application to Monitor Activation State Longitudinally In Vivo." PLOS ONE, vol. 7, no. 2, 2012, e31814. https://doi.org/10.1371/journal.pone.0031814
2. Deng, Qian, et al. "A New Mechanism Regulating Microglial NLRP3 Inflammasome: FMR1 Mediates NLRP3 mRNA Stability." PLOS ONE, vol. 21, no. 2, 2026, e0341867. https://doi.org/10.1371/journal.pone.0341867
3. Distributed under Open Access license CC BY 4.0, without modification.